November 12, 2020European Heart Journal134 citationsOpen Access
View Full PaperInfluence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Structured PICO
Does empagliflozin reduce the risk of heart failure and renal events in patients with chronic heart failure and a reduced ejection fraction receiving sacubitril/valsartan?
P
Population
patients with chronic heart failure and a reduced ejection fraction
I
Intervention
empagliflozin
O
Outcome
heart failure and renal eventshard clinical
Combined treatment with both SGLT2 and neprilysin inhibitors can be expected to yield substantial additional benefits in patients with HFrEF.
Abstract
The effects on empagliflozin to reduce the risk of heart failure and renal events are not diminished in intensively treated patients who are receiving sacubitril/valsartan. Combined treatment with both SGLT2 and neprilysin inhibitors can be expected to yield substantial additional benefits.